Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam plus nalbuphine for painless gastrointestinal endoscopy
ChiCTR2100043228Phase 4Recruiting
- Sponsor
- Shaoxing University Affiliated Hospital
- Start
- Mar 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in gastrointestinal conditions comparing Remimazolam + nalbuphine with Remimazolam + propofol (2 arms). Primary endpoint: Recovery time. Started Mar 2021; status: recruiting.
02
Drugs
remimazolamnalbuphinepropofol
03
Conditions
gastrointestinal conditions
Beyond the preview
Go deeper on ChiCTR2100043228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043228.